SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

Launched by UNIVERSITY OF MIAMI · Jun 6, 2022

Keywords

ClinConnect Summary

The SMART TNT clinical trial is studying a new approach to treat patients with locally advanced rectal cancer, which is a type of cancer that has spread deeper into the rectal wall or to nearby lymph nodes. The goal of this study is to see if giving chemotherapy first, followed by a higher dose of radiation therapy, can help patients achieve a complete response to treatment and potentially avoid surgery altogether.

To participate in this trial, patients should be at least 18 years old and have been newly diagnosed with rectal adenocarcinoma, with the tumor located a certain distance from the rectal opening. They must also meet other health criteria to ensure they can safely undergo the treatment. Participants can expect to receive carefully monitored chemotherapy and radiation therapy, along with regular check-ups to assess their response to treatment. This trial is currently recruiting participants, and it's important to note that certain health conditions and previous treatments may make someone ineligible. If you or a loved one is considering participation, discussing it with a healthcare provider can help determine if it's the right option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with newly diagnosed, biopsy proven, rectal adenocarcinoma.
• • 2. Primary tumor located ≤18 cm from margin verge.
• • 3. Primary tumor either a T3N0 or T1-4 N positive (as defined per pelvic MRI; nodes ≤ 15 mm).
• • 4. ≥ 18 years of age.
• • 5. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• • 6. Serum liver function tests values within the range of 1.5 x Upper Limit of Normal (within 6 weeks of enrollment).
• • 7. Negative pregnancy test for women of child-bearing potential (within 4 weeks of enrollment).
• • 8. Ability to understand and the willingness to sign a written informed consent document.
• • 9. Patient is assessed by a surgeon, medical oncologist and a radiation oncologist and deemed fit for Total Neoadjuvant ChemoTherapy (TNT) and surgery.
• Exclusion Criteria:
• • 1. Metastatic disease on initial work up (Chest and abdomen contrast enhanced CT scan).
• • 2. Synchronous cancer found on colonoscopy.
• • 3. Previous history of pelvic radiotherapy.
• • 4. History of concurrent, active malignancy other than non-metastatic skin cancer within the last 2 years.
• • 5. Symptomatic congestive heart failure of New York Heart Association Class III or IV, unstable angina pectoris or uncontrolled severe cardiac arrhythmia, myocardial infarction within the last 6 months.
• • 6. Psychiatric illness/social situations that would limit compliance with study requirements.
• • 7. Active (acute or chronic) or uncontrolled severe infections requiring intravenous antibiotics or active tuberculosis (TB).
• • 8. Patients with poorly controlled acquired immune deficiency syndrome (AIDS) who are not deemed candidates for FOLFOX, mFOLFIRINOX or CAPOX chemotherapy. Active connective tissue disorders, such as lupus or scleroderma, that, in the opinion of the treating physician may put the patient at high risk for radiation toxicity.
• • 9. Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity
• • 10. Sensory or motor neuropathy ≥ grade 2.
• • 11. Women who are breast feeding.
• • 12. Exclusions due to MRI use in study: ferromagnetic metal in body/eye, pacemaker, defibrillator, other mechanical device, or extreme claustrophobia (medication with anti-anxiety agents, such as Ativan, may be attempted).